Related Experiment Video
Updated: Mar 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Pathogenetic Aspects of Myelodysplastic Syndromes
1a Department of Haematology , Aberdeen Royal Infirmary , Foresterhill, Aberdeen , AB25 2ZN.
Abstract:
The myelodysplastic syndromes (MDS) are acquired clonal disorders of the bone marrow. They were clearly defined in morphological terms by the French-American-British (FAB) group in 1982, as five conditions each with their own diagnostic criteria, but with the shared characteristics of ineffective blood cell production in one or more cell line, morphological dysplasia and a variable propensity to evolve into acute myeloid leukaemia (AML). In clinical practice patients typically present in old age with macrocytic anaemia, cytopenias, monocytosis and accumulation of marrow blast cells leading in time to fatal bone marrow failure or AML. To date treatment is unable to alter the natural history of MDS except in those few individuals who are able to undergo allogeneic progenitor cell transplantation.
Related Concept Videos
Abnormal Proliferation
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Induced Pluripotent Stem Cells
Somatic...

